Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E54.82 EPS (ttm)8.31 Insider Own1.30% Shs Outstand108.02M Perf Week-0.36%
Market Cap49.22B Forward P/E29.74 EPS next Y15.32 Insider Trans-0.50% Shs Float78.29M Perf Month22.70%
Income963.10M PEG2.87 EPS next Q3.13 Inst Own69.70% Short Float3.89% Perf Quarter26.23%
Sales4.98B P/S9.89 EPS this Y39.50% Inst Trans0.15% Short Ratio3.30 Perf Half Y14.22%
Book/sh46.09 P/B9.89 EPS next Y20.91% ROA13.80% Target Price445.33 Perf Year15.52%
Cash/sh12.10 P/C37.66 EPS next 5Y19.12% ROE21.50% 52W Range325.35 - 464.40 Perf YTD24.14%
Dividend- P/FCF35.14 EPS past 5Y38.80% ROI18.20% 52W High-1.87% Beta1.46
Dividend %- Quick Ratio2.60 Sales past 5Y61.30% Gross Margin94.50% 52W Low40.06% ATR11.20
Employees5400 Current Ratio2.80 Sales Q/Q9.80% Oper. Margin28.80% RSI (14)67.18 Volatility2.08% 2.99%
OptionableYes Debt/Eq0.15 EPS Q/Q36.20% Profit Margin19.30% Rel Volume0.72 Prev Close455.70
ShortableYes LT Debt/Eq0.14 EarningsMay 04 BMO Payout0.00% Avg Volume923.99K Price455.70
Recom2.20 SMA204.55% SMA5013.90% SMA20017.78% Volume0 Change0.00%
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Mar-29-17Reiterated UBS Buy $435 → $446
Mar-17-17Initiated Oppenheimer Perform
Mar-09-17Initiated UBS Buy $435
Feb-16-17Downgrade Goldman Buy → Neutral
Jan-06-17Reiterated RBC Capital Mkts Outperform $626 → $598
Jan-06-17Reiterated Chardan Capital Markets Neutral $350 → $345
Dec-20-16Upgrade Credit Suisse Neutral → Outperform
Dec-12-16Upgrade Chardan Capital Markets Sell → Neutral $300 → $350
Nov-07-16Reiterated Chardan Capital Markets Sell $325 → $300
Aug-05-16Downgrade Robert W. Baird Outperform → Neutral $505 → $448
Jun-29-16Initiated Bernstein Outperform
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
May-25-17 10:27AM  Regeneron Presents Positive Phase II Data on HoFH Candidate Zacks
09:30AM  The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene Zacks
May-24-17 05:00PM  Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH PR Newswire
12:13PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
10:27AM  Theravance/Mylan Presents Phase III Data on COPD Candidate Zacks
08:37AM  Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data Zacks
08:15AM  Blog Coverage: Celgene Reported Positive Late Stage Results from Trial of Ozanimod in Patients with Relapsing Multiple Sclerosis Accesswire
07:00AM  Wide-Moat Roche Is Undervalued Morningstar
May-23-17 04:25PM  Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis Investor's Business Daily
03:08PM  Sanofi Genzyme takes on worlds top-selling drugs with new approval American City Business Journals
02:38PM  Charter's Rutledge, CBS's Moonves among highest-paid CEOs Associated Press
02:38PM  Charter's Rutledge, CBS's Moonves among highest-paid CEOs Associated Press
10:25AM  Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis Zacks
May-22-17 06:35PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
06:05PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
05:53PM  Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients GlobeNewswire
05:45PM  Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients PR Newswire
02:08PM  Regeneron And Sanofi Have A Near-Term FDA Catalyst Benzinga
02:04PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : May 22, 2017 Capital Cube
08:30AM  Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session Zacks
08:07AM  These 3 Biotech Stocks Have Ballooned in 2017, but Will They Pop? Motley Fool
May-19-17 04:30PM  Amgen, Gilead, Biogen Won't Lead The Biotech Boom So Who Will? Investor's Business Daily
01:09PM  5 Reasons Big Biotech Could Gain 25%-30% Barrons.com
09:28AM  Regeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 Capital Cube
07:28AM  Vetr Upgrade's REGN's On Price Growth Following Positive Guidance Benzinga
May-18-17 03:44PM  Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments Investor's Business Daily
03:25PM  Regeneron CEO in Boston: drug pricing could be 'the undoing of our industry' American City Business Journals
02:38PM  Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks Investor's Business Daily
01:00PM  Stocks Cling To Gains; Apple, Netflix Lead Nasdaq; Time To Buy Biotechs? Investor's Business Daily
12:43PM  Build Your Investing Watch List With Stock Ratings, Buy Zones, Earnings Investor's Business Daily
11:15AM  Which Companies Are Now Outperforming 95% Of All Stocks? Investor's Business Daily
11:06AM  Recovering Biotech Stock Enters Buy Zone; Earns Rating Upgrade Investor's Business Daily
09:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
May-17-17 09:36AM  Regeneron, Nuance Communications, Waste Management, Waste Connections and Republic Services highlighted as Zacks Bull and Bear of the Day Zacks
07:53AM  Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal Zacks
07:00AM  Bull of the Day: Regeneron (REGN) Zacks
May-15-17 08:33AM  TransEnterix (TRXC) Reports Wider-than-Expected Loss in Q1 Zacks
May-12-17 12:04PM  Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce? Motley Fool
08:50AM  Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up Zacks
08:23AM  Medtronic (MDT) Wins FDA Approval for CRT-P SureScan Suite Zacks
08:06AM  STERIS (STE) Grapples with Headwinds: Should You Dump? Zacks
May-11-17 10:21AM  Hologic (HOLX) Tops Q2 Earnings & Sales, Raises 2017 View Zacks
10:15AM  Genomic Health (GHDX) Misses Q1 Earnings & Sales Estimates Zacks
10:07AM  Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip Zacks
May-10-17 08:30AM  Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death Zacks
May-09-17 04:38AM  Regeneron Pharmaceuticals (REGN) Shares March Higher, Can It Continue? Zacks
May-08-17 09:24AM  Edited Transcript of REGN earnings conference call or presentation 4-May-17 12:30pm GMT Thomson Reuters StreetEvents
08:30AM  Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer PR Newswire
07:30AM  Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy PR Newswire
07:30AM  Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy GlobeNewswire
May-07-17 01:17PM  Regeneron shares poised for rebound: Barron's Reuters
01:01PM  Regeneron shares poised for rebound - Barron's Reuters
May-06-17 12:01AM  [$$] Regeneron's Regeneration Barrons.com
May-05-17 04:37PM  Will 'Comeback Kid' Regeneron Survive Amgen's Cholesterol Squeeze? Investor's Business Daily
09:30AM  Zacks Investment Ideas feature highlights: Regeneron, Edwards Lifesciences, Alexion Pharmaceuticals, Align Technology and Centene Zacks
09:30AM  Regeneron Announces Upcoming Investor Conference Presentations PR Newswire
06:15AM  Oil Slide Puts Market Into Rotation: Cramer's 'Mad Money' Recap (Thursday 5/4/17) TheStreet.com
May-04-17 05:59PM  5 Healthcare Innovators I'm Still Buying Zacks +6.70%
05:50PM  Regeneron Shares Rise After Reporting Better-Than-Expected Sales TheStreet.com
04:56PM  Regeneron Pops On 'Better-Than-Feared' Eye, Cholesterol Drug Sales Investor's Business Daily
04:31PM  The Hot Stock: Regeneron Pharmaceuticals Soars 6.7% Barrons.com
03:33PM  Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates Zacks
03:07PM  US STOCKS-Wall Street stays flat after House clears health bill Reuters
10:37AM  Why Regeneron is Soaring Barrons.com
08:45AM  Regeneron revenue tops estimates, Co backs Eylea sales forecast Reuters
08:18AM  Regeneron (REGN) Q1 Earnings Misses Estimates Zacks
07:30AM  Investor Network: REGENERON PHARMACEUTICALS INC to Host Earnings Call Accesswire
06:40AM  Regeneron misses 1Q profit forecasts Associated Press
06:35AM  Biotech Regeneron's profit jumps 37 pct on higher Eylea sales Reuters
06:30AM  Regeneron Reports First Quarter 2017 Financial and Operating Results PR Newswire
May-03-17 02:43PM  After Gilead Earnings, Buy These Biotech Stocks Zacks
08:22AM  Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More Zacks
May-02-17 08:30AM  Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment PR Newswire
May-01-17 04:53PM  Did Regeneron, Sanofi Just Launch A Blockbuster Drug? Investor's Business Daily
01:45PM  Regeneron: This Could Be Good Barrons.com
08:38AM  6 FDA Events to Watch Out for in May 2017 Zacks
08:12AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : May 1, 2017 Capital Cube
Apr-30-17 11:41AM  5 Big Drugmakers With Important Catalysts in May Motley Fool
Apr-29-17 08:03AM  Is Regeneron (Finally) Getting Back on Track? Motley Fool
Apr-28-17 05:46PM  Regeneron (REGN) to Post Q1 Earnings: What's in the Cards? Zacks +5.97%
10:43AM  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Zacks
09:57AM  Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates Zacks
02:59AM  Genzyme, CHC lift Sanofi's first-quarter figures, upbeat on Dupixent Reuters
01:00AM  Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA PR Newswire
Apr-27-17 09:21AM  Amgen's Q1 Results Highlight the Need for an Acquisition Motley Fool
09:08AM  Dupixent Expected to Be a Solid Addition to Regenerons Portfolio Market Realist
07:39AM  Analysts Recommendations for Regeneron in 1Q17 Market Realist
Apr-26-17 05:28PM  Amgen Trips Amid Rivals: Sales Miss By $100 Million, But Earnings Top Investor's Business Daily
04:33PM  Will Regenerons Revenue Surpass Analysts Estimates in 1Q17? Market Realist
01:35PM  Will Amgen's Rivals Pop On Its Cholesterol-Busting Drug? Investor's Business Daily
Apr-25-17 08:26AM  Earnings Preview: What To Expect From Amgen On Wednesday Forbes
08:00AM  Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
08:00AM  Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection PR Newswire
Apr-24-17 01:00AM  Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis PR Newswire
Apr-21-17 04:15PM  Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Investor's Business Daily
02:22PM  EMA panel recommends nod for Sanofi, Regeneron's arthritis drug Reuters
Apr-20-17 09:31AM  Sanofi Genzyme hit with patent lawsuit over new eczema drug American City Business Journals
Apr-18-17 02:31PM  Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds? Investor's Business Daily
Apr-17-17 09:40AM  Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain Motley Fool
Apr-16-17 02:02PM  3 Big Reasons to Be Bullish on Biotech Stocks Motley Fool
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BROWN MICHAEL SDirectorMay 12Option Exercise177.823,000533,4603,000May 15 04:07 PM
BROWN MICHAEL SDirectorMay 12Sale450.003,0001,350,0000May 15 04:07 PM
BROWN MICHAEL SDirectorMar 29Option Exercise177.821,000177,8201,000Mar 30 04:42 PM
BROWN MICHAEL SDirectorMar 29Sale400.001,000400,0000Mar 30 04:42 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 15Option Exercise20.32195,0793,964,005697,000Dec 19 04:09 PM
SCHLEIFER LEONARD SPresident & CEODec 15Option Exercise20.32250,0005,080,000292,806Dec 19 04:07 PM
BAKER CHARLES ADirectorDec 12Option Exercise18.613,00055,83012,000Dec 14 05:41 PM
BAKER CHARLES ADirectorDec 12Sale392.023,0001,176,0489,000Dec 14 05:41 PM
RYAN ARTHUR FDirectorNov 15Sale429.342,000858,68036,500Nov 16 04:21 PM
GOLDSTEIN JOSEPH LDirectorNov 14Option Exercise273.672,125581,54915,125Nov 15 04:08 PM
GOLDSTEIN JOSEPH LDirectorNov 14Sale450.002,125956,25013,000Nov 15 04:08 PM
VAGELOS P ROYChairman of the BoardNov 07Option Exercise20.3276,8951,562,506515,726Nov 09 04:10 PM
GOLDSTEIN JOSEPH LDirectorJul 29Option Exercise273.672,125581,54915,125Aug 01 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 29Sale425.002,125903,12513,000Aug 01 04:04 PM